A5012360574- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- Hepatitis C virus research
- HIV/AIDS Research and Interventions
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- HIV-related health complications and treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Tuberculosis Research and Epidemiology
- Cytomegalovirus and herpesvirus research
- Liver Diseases and Immunity
- HIV, Drug Use, Sexual Risk
- Hepatitis Viruses Studies and Epidemiology
- Viral-associated cancers and disorders
- Systemic Lupus Erythematosus Research
- Herpesvirus Infections and Treatments
- Mycobacterium research and diagnosis
- Diagnosis and treatment of tuberculosis
- Parasitic Infections and Diagnostics
- Reproductive tract infections research
- Chronic Lymphocytic Leukemia Research
- Infectious Diseases and Tuberculosis
- Liver Disease and Transplantation
- Immune Cell Function and Interaction
- Adolescent Sexual and Reproductive Health
Agenzia Regionale Sanitaria della Puglia
2024
University of Bari Aldo Moro
2013-2022
University of Sassari
2021
Riga East University Hospital
2021
University of Rome Tor Vergata
2020
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani
2005-2019
Azienda Ospedaliera San Gerardo
2019
ASST Fatebenefratelli Sacco
2019
Italian Medicines Agency
2018
Istituti di Ricovero e Cura a Carattere Scientifico
1993-2018
Objective: To evaluate the frequency of discontinuation first highly active antiretroviral regimen (HAART) and factors predictive discontinuing for toxicity failure in a population-based cohort HIV-positive individuals Italy, naïve from antiretrovirals at enrolment. Methods: The study population consisted who initiated HAART had least one follow-up visit. primary end-points were any component drug failure. Survival analyses performed to identify reaching two end-points. Results: Eight...
The molecular epidemiology of HIV-1 in Italy is becoming increasingly complex, mainly due to the spread non-B subtypes and emergence new recombinant forms. We previously characterized outbreak first Italian circulating form (CRF60_BC), occurring among young MSM living Apulia between years 2009 2011. Here we show a 5-year follow-up surveillance trace evolution CRF60_BC investigate its further Italy. collected additional sequences clinical data from patients harboring CRF60_BC, enrolled at...
Infection with drug-resistant human immunodeficiency virus type 1 (HIV-1) can impair the response to combination therapy. Widespread transmission of variants has disturbing potential limiting future therapy options and affecting efficacy postexposure prophylaxis.We determined baseline rate drug resistance in 2208 therapy-naive patients recently chronically infected HIV-1 from 19 European countries during 1996-2002.In Europe, 10 antiretroviral-naive carried viruses > or = drug-resistance...
To evaluate the presence of premature atherosclerotic lesions epiaortic vessels in HIV-1-infected protease inhibitor-(PI) treated patients compared with PI-naive and healthy individuals.One-hundred two HIV-1-positive patients, including 55 PI for at least 12 months 47 either naive or PI-sparing regimens, were subjected to vessel ultrasonography. These data those obtained from 104 individuals.Intima characteristics, pulsation resistance indexes, minimal, peak mean speed evaluated using a...
<h3>Objective.</h3> —To analyze how demographic, clinical, and laboratory characteristics influence the risk of tuberculosis in human immunodeficiency virus (HIV)— infected individuals; to examine incidence associated with change skin test responsiveness HIV-infected, tuberculin-negative, nonanergic individuals. <h3>Design.</h3> —Multicenter cohort study. <h3>Setting.</h3> —Twenty-three infectious disease units public hospitals Italy. <h3>Subjects.</h3> —A consecutive sample 3397...
ABSTRACT The aim of the present pilot study was to compare efficacy and safety trimethoprim (TMP) sulfamethoxazole (SMX) with those standard therapy pyrimethamine (P)-sulfadiazine (S) for treatment toxoplasmic encephalitis in patients AIDS. This a pilot, multicenter, randomized, prospective study. Patients were randomly assigned receive TMP (10 mg/kg body weight/day) SMX (50 mg/kg/day) or P mg daily) S (60 as acute (for 4 weeks) then maintenance 3 months at half original dosage....
The prevalence and the origin of HIV-1 subtype B, most prevalent circulating clade among long-term residents in Europe, have been studied extensively. However spatial diffusion epidemic from perspective virus has not previously traced. In current study we inferred migration history B by way a phylogeography viral sequences sampled 16 European countries Israel. Migration events were phylogenies character reconstruction using parsimony. With regard to dispersal HIV across phylogenies, Europe...
Although HAART suppresses HIV replication, it is often unable to restore immune homeostasis. Consequently, non-AIDS-defining diseases are increasingly seen in treated individuals. This attributed persistent virus expression reservoirs and cell activation. Of note, CD4+ T cells monocyte-macrophages of virologically-suppressed individuals, there continued multi-spliced transcripts encoding regulatory proteins. Among them, Tat essential for gene either primary infection or reactivation during...
The purpose of our cohort study was to quantify olfactory deficits in Coronavirus disease 2019 (COVID-19) patients using Sniffin' Sticks and a pre-post design evaluate recovery. Thirty adult with laboratory-confirmed mild moderate forms COVID-19 underwent quantitative test performed the (SST; Burghardt, Wedel, Germany), considering threshold (T), odor discrimination (D), identification (I). Results were presented as composite TDI score (range 1-48) that used define functional anosmia (TDI ≤...
Abstract Background Few data are reported in the literature about outcome of patients with severe extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) infections treated ceftolozane/tazobactam (C/T), empiric or definitive therapy. Methods A multicenter retrospective study was performed Italy (June 2016–June 2019). Successful clinical defined as complete resolution signs/symptoms related to ESBL-E infection and lack microbiological evidence infection. The primary end point...
Objectives: To evaluate the determinants of HIV-1 RNA shedding in cervicovaginal secretions and effects antiretroviral therapy a group infected women. Methods: A total 122 women from whom paired peripheral blood lavage samples were available enrolled study. was quantified plasma cell-free fraction lavages by nucleic acid sequence-based amplification assay (lower limit detection 80 copies/ml). Results: Seventy-one per cent had detectable viral load this appeared to be correlated degree...
Summary To study incidence and risk factors of heterosexually transmitted HIV infection, we followed a cohort 343 seronegative women, stable, monogamous partners infected men whose only acquiring was sexual exposure to the partner. Nineteen seroconversions occurred in 529.6 person years (py) observation, yielding an rate 3.6 per 100 py. The 7.2 py among women who did not always use or never used condoms 1.1 those them [relative (RR) 6.6, 95% confidence interval (CI) 1.9–21.9]. Anal sex...
Adipose tissue alterations (ATAs) were clinically assessed in 2258 HIV-1–infected outpatients consecutively observed 6 Italian clinical centers and found to be present 29.5% of the men 41.9% women. A logistic regression model including age, HIV disease Centers for Disease Control stage, CD4 cell counts, RNA load, duration antiretroviral therapy, number drugs taken, use d4T showed that had a 0.47 adjusted risk presenting with ATAs (95% CI: 0.38–0.58, P < 0.0001). The risks having (except...
The role of mutations in protease (PR) and reverse-transcriptase (RT) human immunodeficiency virus (HIV) predicting virologic failure was assessed 248 antiretroviral-naive HIV-positive patients who began a PR inhibitor—containing antiretroviral regimen. Genotypic testing performed on plasma samples stored before the start therapy. Twenty-seven (10.9%) had RT, 5 (2%) carried primary PR, 131 (52.8%) showed only secondary mutations. Virologic at week 24 occurred 62 (25.0%) patients. There...
The genetic barrier, defined as the number of mutations required to overcome drug-selective pressure, is an important factor for development HIV drug resistance. Because high variability between subtypes, particular HIV-1 subtypes could have different barriers resistance substitutions. This study compared barrier using some 2000 sequences (>600 non-B subtype) isolated from anti-retroviral-naive patients in Europe.The was calculated sum transitions (scored 1) and/or transversions (2.5)...
Background. There is lack of data on the incidence liver fibrosis (LF) progression in patients with human immunodeficiency virus (HIV) monoinfection and risk factors for LF. Methods. We performed an observational prospective study a cohort HIV-infected who had initiated highly active antiretroviral therapy (HAART). FIB-4 aspartate aminotransferase (AST)-to-platelet ratio index (APRI) were assessed. The concordance between 2 scores was assessed by weighted kappa coefficient. Kaplan-Meier...
Objectives We studied survival and associated risk factors in an Italian nationwide cohort of HIV-infected individuals after AIDS-defining cancer (ADC) or non-AIDS-defining (NADC) diagnosis the modern cART era. Methods Multi-center, retrospective, observational study HIV patients included MASTER Cohort with a from January 1998 to September 2012. Malignancies were divided into ADC NADC on basis Centre for Disease Control-1993 classification. Recurrence metastases excluded. Survivals estimated...